Enhanced potency of perfluorinated thalidomide derivatives for inhibition of LPS-induced tumor necrosis factor-α production is associated with a change of mechanism of action

Bioorganic and Medicinal Chemistry Letters

Volumn 8, Issue 9, 1998, Pages 1071-1076

  Niwayama, Satomi ^a   Loh, Christine ^a   Turk, Benjamin E ^a   Liu, Jun O ^a   Miyachi, Hiroyuki ^b   Hashimoto, Yuichi ^b  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA METHYLTHALIDOMIDE; LIPOPOLYSACCHARIDE; THALIDOMIDE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; DRUG MECHANISM; DRUG POTENCY; DRUG SYNTHESIS; ENANTIOMER; FLUORINATION; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

CELL LINE; DRUG DESIGN; HUMANS; LIPOPOLYSACCHARIDES; MONOCYTES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032080615     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(98)00171-1     Document Type: Article

References (23)

1. 1. (a) Koch, H. Prog. Med. Chem. Elsevier: New York, 1985; pp 165-242.
2. (b) Gunzler, V. Drug Safety 1992, 7, 116.
3. 2. (a) Sampaio, E. P.; Sarno, E. N.; Galilly, R.; Cohn, Z. A.; Kaplan, G. J. Exp. Med. 1991, 173, 699.
4. (b) Moreira, A. L.; Sampaio, E. P.; Zmuidzinas, A.; Frindt, P.; Smith, K. A.; Kaplan, G. J. Exp. Med. 1993, 177, 1675.
5. 3. (a) Turk, B. E.; Jiang, H.; Liu, J. O. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 7552.
6. (b) Moore, D. F.; Rosenfeld, M. R.; Gribbon, P. M.; Winlove, C. P.; Tsai, C. M. Inflammation 1997, 21, 69.
7. (c) Boutten, A.; Dehoux, M.; Deschenes, M.; Rouzeau, J.-D., Bories, P. N.; Durand, G. Eur. J. Immunol. 1992, 22, 2687.
8. 4. (a) Niwayama, S.; Turk, B. E.; Liu, J. O. J. Med. Chem. 1996, 39, 3044.
9. (b) Shibata, Y.; Sasaki, K.; Hashimoto, Y.; Iwasaki, S. Biochem. Biophys. Res. Commun. 1994, 205, 1992.
10. 5. (a) Blaschke, G.; Klaft, H. P.; Fickentscher, K.; Koehler, F. Arzneim.-Forsch. 1979, 29, 1640.
11. (b) Wnendt, S.; Finkam, M.; Winter, W.; Ossig, J.; Raabe, G.; Zwingenberger, K. Chirality 1996, 8, 390.
12. (c) Nishimura, K.; Hashimoto, Y.; Iwasaki, S. Chem. Pharm. Bull. 1994, 42, 1157.
13. 6. Knoche, B.; Blaschke, G. J. Chromatogr. 1994, A666, 235.
14. 7. Miyachi, H.; Azuma, A.; Hioki, E.; Iwasaki, S.; Hashimoto, Y. Bioorg. Med. Chem. Lett., 1996, 6, 2293.
15. 8. Davies, S. G.; Ichihara, O. Tetrahedron: Asymmetry 1991, 2, 183.
16. +)
17. 50 values: (S)-4; 432 (±30) nM, (R)-4; 345 (±55) nM, (±)-4; 365 (±30) nM, (S)-6; 101 (±1) nM, (R)-6; 108 (±10) nM, (±)-6; 101 (±1) nM, (S)-7; 177 (±1) nM, (R)-7; 180 (±24) nM, (±)-7; 166 (±23) nM. All the assays were conducted at least in duplicate. None of the compounds used in this assay showed significant toxicity up to a dose of 1 μM for tetrafluorophthalimides or 200 μM for α-methylthalidomide, as judged by Trypan Blue exclusion.
18. 11. In this system, racemic thalidomide (1) and (S)-α-methylthalidomide have roughly the same potency.
19. 12b (a) Corral, L. G.; Muller, G. W.; Moreita, A. L.; Chen, Y.; Wu, M.; Stirling, D.; Kaplan, G. Mol. Medicine 1996, 2, 506.
20. (b) Muller, G.; Corral, L. G.; Shire, M. G.; Wang, H.; Moreira, A.; Kaplan, G.; Stirling, D. I. J. Med. Chem. 1996, 39, 3238.
21. 13. (a) Miyachi, H.; Ogasawa, A.; Azuma, A.; Hashimoto, Y. Bioorg. Med. Chem. 1997, 5, 2095.
22. (b) Miyachi, H.; Azuma, A.; Ogasawara, A.; Uchimura, E.; Watanabe, N.; Kobayashi, Y.; Kato, F.; Kato, M.; Hashimoto, Y. J. Med. Chem., 1997, 40, 2858.
23. 14. Organofluorine Compounds in Medicinal Chemistry and Biomedical Applications; Filler, R.; Kobayashi, Y.; Yagupolskii, L. M., Eds.; Elsevier: Amsterdam, 1993.